Raymond James and Cantor both released bullish notes on uniQure (NASDAQ:QURE) Tuesday in the wake of news that the company ...

The company now says that, during a recent meeting with the FDA, the two parties agreed on some key elements for an ...

UniQure (NASDAQ:QURE) stock shot up 90% Tuesday morning on news that the company had reached an agreement with the FDA on key ...

Want to stay on top of the science and politics driving biotech today? Sign up to get our biotech newsletter in your inbox.

Crucially for the Netherlands-based biopharma company, the FDA has said that the composite Unified Huntington's Disease ...

The FDA will allow uniQure NV to seek accelerated approval for its Huntington’s disease gene therapy more than doubled the ...

N.V. announced that the company reached agreement with the U.S. Food and Drug Administration, FDA, on key elements of an ...

Pick the best stocks and maximize your portfolio: uniQure ( (QURE)) has provided an update. uniQure has reached an agreement with the FDA on critical elements for the Accelerated Approval pathway for ...

UniQure shares more than doubled after the company reached agreement with the Food and Drug Administration on key elements of an accelerated approval pathway for AMT-130, a potential treatment for ...

Qure's AMT-130 shows promising results for Huntington’s disease. Learn why QURE stock faces commercialization challenges ...

In a Type B meeting, the FDA signified that it will allow uniQure to use a natural history control, the composite Unified ...

Qure stock surges after FDA agrees on an accelerated approval pathway for its Huntington's disease treatment, AMT-130.